Co-Diagnostics Inc

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

CODX$0.32+24.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Three Months Ended March 31,
	2025	2024
Product revenue	$50,277	$252,745
Grant revenue	-	215,109
Total revenue	50,277	467,854
Cost of revenue	21,590	234,505
Gross profit	28,687	233,349
Operating expenses
Sales and marketing	657,030	1,563,682
General and administrative	2,773,149	2,918,803
Research and development	4,870,019	5,679,678
Depreciation and amortization	280,445	330,573
Total operating expenses	8,580,643	10,492,736
Loss from operations	(8,551,956)	(10,259,387)
Other income, net
Interest income, net	13,601	362,733
Realized gain on investments	301,465	228,070
Gain on remeasurement of acquisition contingencies	717,067	450,260
Loss on equity method investment in joint venture	(1,444)	(70,955)
Total other income, net	1,030,689	970,108
Loss before income taxes	(7,521,267)	(9,289,279)
Income tax provision	12,004	22,764
Net loss	$(7,533,271)	$(9,312,043)
Other comprehensive income (loss)
Change in net unrealized gains (losses) on marketable securities, net of tax	(87,790)	79,855
Total other comprehensive income (loss)	$(87,790)	$79,855
Comprehensive loss	$(7,621,061)	$(9,232,188)
Loss per common share:
Basic and Diluted	$(0.24)	$(0.31)
Weighted average shares outstanding:
Basic and Diluted	32,048,953	29,842,874

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.